{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+Breast+Adenocarcinoma", "query": { "condition": "Hormone Receptor Positive Breast Adenocarcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 65, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hormone+Receptor+Positive+Breast+Adenocarcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T01:10:47.658Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04379570", "title": "Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "HER2 Negative Breast Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Invasive Breast Carcinoma", "Prognostic Stage I Breast Cancer AJCC v8", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8" ], "interventions": [ { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Text Message-based Navigation Intervention", "type": "OTHER" }, { "name": "Motivational Interviewing", "type": "BEHAVIORAL" }, { "name": "Best Practice", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1167, "start_date": "2021-02-15", "completion_date": "2026-08-31", "has_results": false, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 526, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 406 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04379570" }, { "nct_id": "NCT01272037", "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Ductal Carcinoma In Situ", "Invasive Breast Carcinoma", "Multicentric Breast Carcinoma", "Multifocal Breast Carcinoma", "Synchronous Bilateral Breast Carcinoma" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Systemic Chemotherapy", "type": "DRUG" }, { "name": "Tamoxifen Citrate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 5018, "start_date": "2011-02-28", "completion_date": "2027-01-08", "has_results": true, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 1436, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 882 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01272037" }, { "nct_id": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Oligoastrocytoma", "Anaplastic Oligodendroglioma", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "Glioblastoma", "Hormone-Resistant Prostate Cancer", "Metastatic Prostate Carcinoma", "Metastatic Renal Cell Cancer", "Recurrent Adult Brain Neoplasm", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Hepatocellular Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Melanoma", "Recurrent Ovarian Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Uterine Corpus Carcinoma", "Resectable Hepatocellular Carcinoma", "Sarcoma", "Stage IA Breast Cancer", "Stage IA Ovarian Cancer", "Stage IA Uterine Corpus Cancer", "Stage IB Breast Cancer", "Stage IB Ovarian Cancer", "Stage IB Uterine Corpus Cancer", "Stage IC Ovarian Cancer", "Stage II Uterine Corpus Cancer", "Stage IIA Breast Cancer", "Stage IIA Lung Carcinoma", "Stage IIA Ovarian Cancer", "Stage IIB Breast Cancer", "Stage IIB Esophageal Cancer", "Stage IIB Lung Carcinoma", "Stage IIB Ovarian Cancer", "Stage IIB Skin Melanoma", "Stage IIC Ovarian Cancer", "Stage IIC Skin Melanoma", "Stage IIIA Breast Cancer", "Stage IIIA Esophageal Cancer", "Stage IIIA Lung Carcinoma", "Stage IIIA Ovarian Cancer", "Stage IIIA Skin Melanoma", "Stage IIIA Uterine Corpus Cancer", "Stage IIIB Breast Cancer", "Stage IIIB Esophageal Cancer", "Stage IIIB Ovarian Cancer", "Stage IIIB Skin Melanoma", "Stage IIIB Uterine Corpus Cancer", "Stage IIIC Breast Cancer", "Stage IIIC Esophageal Cancer", "Stage IIIC Ovarian Cancer", "Stage IIIC Skin Melanoma", "Stage IIIC Uterine Corpus Cancer", "Stage IV Bladder Urothelial Carcinoma", "Stage IV Esophageal Cancer", "Stage IV Ovarian Cancer", "Stage IV Prostate Cancer", "Stage IV Skin Melanoma", "Stage IVA Uterine Corpus Cancer", "Stage IVB Uterine Corpus Cancer" ], "interventions": [ { "name": "DEC-205/NY-ESO-1 Fusion Protein CDX-1401", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2012-03", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2016-10-04", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01522820" }, { "nct_id": "NCT04505826", "title": "A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone Receptor Positive Breast Carcinoma", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "OP-1250", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olema Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 153, "start_date": "2020-08-13", "completion_date": "2024-07-30", "has_results": true, "last_update_posted_date": "2026-05-11", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 15, "location_summary": "Los Angeles, California • Aurora, Colorado • Deerfield Beach, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04505826" }, { "nct_id": "NCT04316117", "title": "Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage IV Breast Cancer AJCC v8", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Breast Carcinoma", "Prognostic Stage IV Breast Cancer AJCC v8" ], "interventions": [ { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2020-09-15", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-06-18", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 98, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04316117" }, { "nct_id": "NCT05568472", "title": "Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Endocrine Drug Therapy", "type": "PROCEDURE" }, { "name": "Health Education", "type": "BEHAVIORAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Symptom Specific Assessment Tool", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 565, "start_date": "2023-03-29", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 489, "location_summary": "Kingman, Arizona • Phoenix, Arizona • Antioch, California + 333 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Antioch", "state": "California" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05568472" }, { "nct_id": "NCT07044310", "title": "5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Mineral Density Test", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "WBF-038", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 38, "start_date": "2025-07-25", "completion_date": "2027-07-25", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07044310" }, { "nct_id": "NCT02115282", "title": "Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Breast Adenocarcinoma", "HER2/Neu Negative", "Locally Advanced Breast Carcinoma", "Metastatic Breast Carcinoma", "Recurrent Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Entinostat", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" }, { "name": "Goserelin Acetate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Placebo Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 608, "start_date": "2014-03-29", "completion_date": "2026-06-02", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 654, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 461 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Carmichael", "state": "California" }, { "city": "Chico", "state": "California" }, { "city": "Chico", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02115282" }, { "nct_id": "NCT01177397", "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma", "Diffuse Large B-Cell Lymphoma", "Glioblastoma Multiforme", "Hepatocellular Carcinoma", "Non-Small Cell Lung Cancer", "Neuroendocrine Tumors of Non-Pancreatic Origin", "Hormone Receptor-Positive Breast Cancer" ], "interventions": [ { "name": "CC-223", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2010-07-20", "completion_date": "2016-12-09", "has_results": true, "last_update_posted_date": "2022-12-13", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 10, "location_summary": "Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01177397" }, { "nct_id": "NCT03845166", "title": "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Malignant", "Renal Cell Carcinoma", "Hormone Receptor Positive Breast Carcinoma", "Metastatic Castration-resistant Prostate Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "XL092", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Exelixis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 325, "start_date": "2019-03-20", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2024-11-19", "last_synced_at": "2026-06-26T01:10:47.658Z", "location_count": 40, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 33 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03845166" } ] }